KR20010040427A - 생적합성 이식물용 조성물 및 방법 - Google Patents
생적합성 이식물용 조성물 및 방법 Download PDFInfo
- Publication number
- KR20010040427A KR20010040427A KR1020007008201A KR20007008201A KR20010040427A KR 20010040427 A KR20010040427 A KR 20010040427A KR 1020007008201 A KR1020007008201 A KR 1020007008201A KR 20007008201 A KR20007008201 A KR 20007008201A KR 20010040427 A KR20010040427 A KR 20010040427A
- Authority
- KR
- South Korea
- Prior art keywords
- membrane
- group
- implant
- poly
- xylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007943 implant Substances 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title abstract description 12
- 125000003118 aryl group Chemical group 0.000 claims abstract description 27
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 25
- 230000002163 immunogen Effects 0.000 claims abstract description 9
- 239000012528 membrane Substances 0.000 claims description 57
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 30
- 239000011148 porous material Substances 0.000 claims description 18
- 102000004877 Insulin Human genes 0.000 claims description 15
- 108090001061 Insulin Proteins 0.000 claims description 15
- 229940125396 insulin Drugs 0.000 claims description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 9
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 6
- 229960003638 dopamine Drugs 0.000 claims description 6
- 239000008096 xylene Substances 0.000 claims description 6
- UZPZYFDULMKDMB-UHFFFAOYSA-N 1,2-dichloro-3,4-dimethylbenzene Chemical group CC1=CC=C(Cl)C(Cl)=C1C UZPZYFDULMKDMB-UHFFFAOYSA-N 0.000 claims description 5
- 239000005495 thyroid hormone Substances 0.000 claims description 4
- 229940036555 thyroid hormone Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229920005597 polymer membrane Polymers 0.000 claims 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 46
- 238000000576 coating method Methods 0.000 abstract description 40
- 230000004224 protection Effects 0.000 abstract description 6
- 241000124008 Mammalia Species 0.000 abstract description 5
- 230000028993 immune response Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 description 24
- 239000011248 coating agent Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 239000000463 material Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 235000010290 biphenyl Nutrition 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000008073 immune recognition Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 150000002790 naphthalenes Chemical class 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 229920003366 poly(p-phenylene terephthalamide) Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011253 protective coating Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 2
- 229920004943 Delrin® Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- -1 cytonutrients Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 102000034240 fibrous proteins Human genes 0.000 description 2
- 108091005899 fibrous proteins Proteins 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000001771 vacuum deposition Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 241000158500 Platanus racemosa Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000009791 fibrotic reaction Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000889 poly(m-phenylene isophthalamide) Polymers 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/013,750 US5922339A (en) | 1998-01-27 | 1998-01-27 | Compositions and methods for biocompatible implants |
| US09/013,750 | 1998-01-27 | ||
| PCT/US1999/001051 WO1999037339A2 (en) | 1998-01-27 | 1999-01-19 | Compositions and methods for biocompatible implants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010040427A true KR20010040427A (ko) | 2001-05-15 |
Family
ID=21761555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007008201A Withdrawn KR20010040427A (ko) | 1998-01-27 | 1999-01-19 | 생적합성 이식물용 조성물 및 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5922339A (https=) |
| EP (1) | EP1051209B9 (https=) |
| JP (1) | JP2002500930A (https=) |
| KR (1) | KR20010040427A (https=) |
| AT (1) | ATE228864T1 (https=) |
| AU (1) | AU743253B2 (https=) |
| CA (1) | CA2318808A1 (https=) |
| DE (1) | DE69904293T2 (https=) |
| WO (1) | WO1999037339A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551618B2 (en) * | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| DE10047300A1 (de) * | 2000-09-25 | 2002-04-18 | Gustav Steinhoff | Bioartifizielles Verbundmaterial und Verfahren zu seiner Herstellung |
| US7179283B2 (en) * | 2001-11-02 | 2007-02-20 | Scimed Life Systems, Inc. | Vapor deposition process for producing a stent-graft and a stent-graft produced therefrom |
| WO2003072157A1 (en) | 2002-02-21 | 2003-09-04 | Encelle, Inc. | Immobilized bioactive hydrogel matrices as surface coatings |
| US20080086792A1 (en) | 2006-10-13 | 2008-04-17 | Thomas Charles Kuracina | Method and apparatus for diverting sweat, liquid, moisture or the like from an eye |
| WO2008098054A2 (en) | 2007-02-06 | 2008-08-14 | Pioneer Surgical Technology, Inc. | Intervertebral implant devices and methods for insertion thereof |
| US9132021B2 (en) | 2011-10-07 | 2015-09-15 | Pioneer Surgical Technology, Inc. | Intervertebral implant |
| JP2014532713A (ja) | 2011-11-02 | 2014-12-08 | ハルシオン，インコーポレイテッド | 創傷処置の方法及び組成物 |
| ES2559467T3 (es) | 2011-12-23 | 2016-02-12 | Pioneer Surgical Technology, Inc. | Matriz continua con partículas osteoconductoras dispersadas en la misma, procedimiento de formación, y su uso para regenerar el hueso con la misma |
| EP3678602A4 (en) | 2017-09-08 | 2021-10-06 | Pioneer Surgical Technology, Inc. | DISC IMPLANTS, INSTRUMENTS AND PROCEDURES |
| USD907771S1 (en) | 2017-10-09 | 2021-01-12 | Pioneer Surgical Technology, Inc. | Intervertebral implant |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4340458A (en) * | 1980-06-02 | 1982-07-20 | Joslin Diabetes Center, Inc. | Glucose sensor |
| DE3216005C2 (de) * | 1982-04-29 | 1987-02-12 | Serag-Wiessner Catgutfabriken GmbH, 8674 Naila | Verwendung eines vollaromatischen Polyamids mit Phenyleneinheiten und Carbonamidbrücken als Fasermaterial für die chirurgische Wundversorgung, insbesondere für chirurgische Nähzwecke |
| EP0138150A3 (en) * | 1983-10-05 | 1988-06-01 | E.I. Du Pont De Nemours And Company | Diagnostic electrode membranes utilizing specific enzyme/ionophore pairs |
| US4868121A (en) * | 1985-02-07 | 1989-09-19 | Mcdonnell Douglas Corporation | Islet isolation process |
| GB8604497D0 (en) * | 1986-02-24 | 1986-04-03 | Connaught Lab | Separation of islets of langerhans |
| US4756835A (en) * | 1986-08-29 | 1988-07-12 | Advanced Polymer Technology, Inc. | Permeable membranes having high flux-density and low fouling-propensity |
| US4794090A (en) * | 1986-09-26 | 1988-12-27 | W. R. Grace & Co.-Conn. | Immobilization support for biologicals |
| US4788271A (en) * | 1987-03-23 | 1988-11-29 | The United States Of America As Represented By The United States National Aeronautics And Space Administration | Polyphenylquinoxalines containing alkylenedioxy groups |
| US5079160A (en) * | 1987-06-08 | 1992-01-07 | Lacy Paul E | Method to isolate clusters of cell subtypes from organs |
| US5151183A (en) * | 1989-05-18 | 1992-09-29 | Allied-Signal Inc. | Reduction of membrane fouling by surface fluorination |
| FR2669527B1 (fr) * | 1990-11-23 | 1998-12-11 | Asa Laboratoires Prothaid | Orthese de renfort pour le remplacement d'un ligament deficient par un transplant autologue. |
| NL9002764A (nl) * | 1990-12-14 | 1992-07-01 | Tno | Elektrode, voorzien van een polymeerbekleding met een daaraan gebonden redox-enzym. |
| CA2109085C (en) * | 1991-04-25 | 2003-03-11 | Keith E. Dionne | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
| AU3274693A (en) * | 1991-12-31 | 1993-07-28 | Abbott Laboratories | Composite membrane |
| JP3291297B2 (ja) * | 1992-02-24 | 2002-06-10 | エンセル，インコーポレイテッド | 生物人工内分泌装置 |
| AU5957094A (en) * | 1993-01-15 | 1994-08-15 | Allied-Signal Inc. | Process for producing ion exchange membranes, and the ion exchange membranes produced thereby |
| AU681240C (en) * | 1994-01-13 | 2006-12-07 | Rogosin Institute, The | Macroencapsulated secretory cells |
-
1998
- 1998-01-27 US US09/013,750 patent/US5922339A/en not_active Expired - Fee Related
-
1999
- 1999-01-19 JP JP2000528317A patent/JP2002500930A/ja active Pending
- 1999-01-19 DE DE69904293T patent/DE69904293T2/de not_active Expired - Lifetime
- 1999-01-19 KR KR1020007008201A patent/KR20010040427A/ko not_active Withdrawn
- 1999-01-19 AT AT99902348T patent/ATE228864T1/de not_active IP Right Cessation
- 1999-01-19 CA CA002318808A patent/CA2318808A1/en not_active Abandoned
- 1999-01-19 AU AU22350/99A patent/AU743253B2/en not_active Ceased
- 1999-01-19 WO PCT/US1999/001051 patent/WO1999037339A2/en not_active Ceased
- 1999-01-19 EP EP99902348A patent/EP1051209B9/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999037339A3 (en) | 1999-09-30 |
| US5922339A (en) | 1999-07-13 |
| JP2002500930A (ja) | 2002-01-15 |
| ATE228864T1 (de) | 2002-12-15 |
| EP1051209A2 (en) | 2000-11-15 |
| EP1051209B1 (en) | 2002-12-04 |
| AU2235099A (en) | 1999-08-09 |
| DE69904293D1 (de) | 2003-01-16 |
| EP1051209B9 (en) | 2003-09-10 |
| WO1999037339A2 (en) | 1999-07-29 |
| CA2318808A1 (en) | 1999-07-29 |
| AU743253B2 (en) | 2002-01-24 |
| DE69904293T2 (de) | 2003-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2354060C (en) | Apparatus and method for control of tissue/implant interactions | |
| La Flamme et al. | Biocompatibility of nanoporous alumina membranes for immunoisolation | |
| Alexandre et al. | Biocompatibility and hemocompatibility of polyvinyl alcohol hydrogel used for vascular grafting—In vitro and in vivo studies | |
| Ratner et al. | Synthetic hydrogels for biomedical applications | |
| EP1326968B1 (en) | Non-disruptive three-dimensional culture and harvest system for anchorage-dependent cells | |
| JPH01501362A (ja) | 人工マトリックスを用いる制御された細胞移植による器官のキメラ新生形態形成 | |
| Sipehia et al. | Enhanced attachment and growth of human endothelial cells derived from umbilical veins on ammonia plasma modified surfaces of PTFE and ePTFE synthetic vascular graft biomaterials | |
| US5932207A (en) | Complex active ingredient for the production of biological parts, especially organs for living organisms: method for the production of the same and its use | |
| CA2194493A1 (en) | Compositions and methods for a bioartificial extracellular matrix | |
| CA2121040A1 (en) | Prevascularized polymeric implants for organ transplantation | |
| EP0502949A1 (en) | Homologous guluronic acid alginate coating composition for in-vivo application and implantation and method of using same | |
| Piskin et al. | Polymeric biomaterials | |
| JP2000507202A (ja) | 生体人工装置及びそのための細胞マトリックス | |
| JP7418363B2 (ja) | バイオ人工血管膵臓 | |
| KR20010040427A (ko) | 생적합성 이식물용 조성물 및 방법 | |
| Yang et al. | Hollow fibers for hepatocyte encapsulation and transplantation: studies of survival and function in rats | |
| Mokrý et al. | Biocompatibility of HEMA copolymers designed for treatment of CNS diseases with polymer‐encapsulated cells | |
| Ortega et al. | Short-term immunosuppression enhances long-term survival of bovine chromaffin cell xenografts in rat CNS | |
| Kuo et al. | Self-assembled ternary poly (vinyl alcohol)-alginate-gelatin hydrogel with controlled-release nanoparticles for pancreatic differentiation of iPS cells | |
| Han et al. | Hydrogel–electrospun fiber mat composite coatings for neural prostheses | |
| EP0577719A1 (en) | ARTIFICIAL PANCREATIC PERFUSION DEVICE PROVIDED WITH A RESESTING MATRIX. | |
| Chen et al. | 3D printed VEGF-CPO biomaterial scaffold to promote subcutaneous vascularization and survival of transplanted islets for the treatment of diabetes | |
| Davies et al. | In vitro assessment of the biological activity of basic fibroblast growth factor released from various polymers and biomatrices | |
| BERNHARD et al. | Development of a nonthrombogenic collagenous blood-prosthetic interface | |
| Sevastianov et al. | A biomedical cell product for the regeneration of articular cartilage: Biocompatible and histomorphological properties (An experimental model of subcutaneous implantation) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20000727 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |